


Hepatitis C: State of Medicaid Access Report Card

District of Columbia



Grade	Recommendations to Improve Patient Access
A+	<ul style="list-style-type: none"> Continue to ensure broad access to HCV treatment.

State Overview

As of October 2023, 283,612 individuals were enrolled in Medicaid and CHIP.¹ As of 2016, an estimated 12,700 people were living with HCV in the District of Columbia.² As of July 1, 2022, 88% of District of Columbia Medicaid beneficiaries were enrolled in a Managed Care Organization (MCO), with the other 12% enrolled in FFS.³ The District of Columbia contracts with four Medicaid MCOs: MedStar Family Choice, AmeriHealth Caritas DC, Amerigroup DC, and Health Services for Children with Special Needs.⁴

The District of Columbia Preferred Drug List designates Mavyret, sofosbuvir/velpatasvir, and Vosevi as preferred regimens.⁵

Deductions		Policy
Prior Authorization		Effective September 1, 2022, prior authorization is not required for preferred HCV treatment regimens. ⁶
Fibrosis Restrictions		DC Medicaid does not impose fibrosis restrictions. ⁷
Substance Use Restrictions		DC Medicaid does not appear to impose substance use restrictions. ⁸
Prescriber Restrictions		DC Medicaid does not impose prescriber restrictions. ⁹
Retreatment Restrictions		DC Medicaid does not impose retreatment restrictions, and notes that “retreatment shall be in accordance with current American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) Hepatitis C treatment guidelines.” ¹⁰
Access in Managed Care		All MCOs (AmeriHealth Caritas DC, ¹¹ CareFirst Community Health Plan, ¹² and Medstar Family Choice ¹³) impose the same requirements as FFS.
Additional Restrictions		DC Medicaid does not appear to impose additional restrictions for preferred regimens. ¹⁴
Total Deductions	0	Total Score [100-Deductions]
		100
		Grade
		A+

Contact Your State Officials

Medicaid Office:¹⁵ **Melisa Byrd, Medicaid Director, Department of Health Care Finance, District of Columbia**
One Judiciary Square 441 4th Street, N.W., Washington, DC 20001; Telephone: (202) 442-9075; Email Address: melisa.byrd@dc.gov.

Pharmacy & Therapeutics Committee:¹⁶ **Charlene Fairfax, RPh, Senior Pharmacist, Department of Health Care Finance**
441 Fourth Street NW, Suite 900, Washington, DC 20001; Telephone: (202) 442-9076; Email Address: charlene.fairfax@dc.gov.

Key Sources

Preferred Drug List: [DC Department of Health Care Finance, Preferred Drug List \(Dec. 22, 2023\)](#).
Clinical Criteria: [DC Department of Health Care Finance, Revision of Hepatitis C Treatment Coverage Policy \(August 24, 2022\)](#).

-
- ¹ Centers for Medicare & Medicaid Services, Medicaid & CHIP in DC, <https://perma.cc/HBJ2-N2TR>.
 - ² HepVu, Local Data: DC, <https://perma.cc/2TFT-SU3G>.
 - ³ Kaiser Family Foundation, Share of Medicaid Population Covered Under Different Delivery Systems, <https://perma.cc/EMN8-QR8B>.
 - ⁴ DC Medicaid, Managed Care Information, <https://perma.cc/EY4K-LF9V>.
 - ⁵ Preferred Drug List.
 - ⁶ Clinical Criteria.
 - ⁷ Clinical Criteria.
 - ⁸ Clinical Criteria.
 - ⁹ Clinical Criteria.
 - ¹⁰ Clinical Criteria.
 - ¹¹ AmeriHealth Caritas District of Columbia, Medicaid Drug Formulary, <https://perma.cc/T35Y-MPTU>.
 - ¹² CareFirst Community Health Plan District of Columbia, Preferred Drug List (Sept. 1, 2022), <https://perma.cc/9P9V-G5MA>.
 - ¹³ Medstar Family Choice, Medicaid Drug Formulary, <https://perma.cc/24FC-Z5WN>.
 - ¹⁴ Clinical Criteria.
 - ¹⁵ Medicaid Directors, National Association of Medicaid Directors, <https://perma.cc/7KTL-ULKZ>.
 - ¹⁶ District of Columbia Department of Health Care Finance, Contact Us, <https://perma.cc/V7NE-72QM>.